321550.KQ TiumBio Co. Ltd
- Market cap
- KRW 109B
- P/E
- -
- P/B
- 3.13x
- ROE
- -53.8%
- Dividend yield
- -
- Fundamental score
- 1.1/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 321550.KQ undervalued?
Graham numberThe Graham number of TiumBio Co. Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
TiumBio Co. Ltd fundamental analysis
4 of 21 checks passedROE 0/2
Low return on equity (-53.8%), below 10%.
ROA 0/1
Return on assets (-21.3%) is below the industry median (1.4%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share did not grow over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 1/1
Last year's EPS growth (23.6%) is above the industry median (1.8%).
Revenue Growth 2/2
Revenue grew 10.5% a year over the past 3 years.
Short-term Liquidity 0/1
Current assets do not cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 2/2
Low debt to equity (29.1%), 40% or less.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Cash Runway 0/2
Cash covers 0.2 years of the current cash burn.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 0/1
Price to book (3.1x) is above the industry median (0.9x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
TiumBio Co. Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About TiumBio Co. Ltd
TiumBio Co., Ltd., a drug discovery company, researches and develops therapeutics for patients with unaddressed rare diseases. The company's products pipeline includes chemical entity-based drugs and biopharmaceuticals comprising NCE401, NCE403, NCE406, and NBP604. It has a collaboration agreement with Oncodesign Société Anonyme for the research and development of fibrosis drug candidates. The company was founded in 2016 and is based in Seongnam-si, South Korea.
Full company profileTiumBio Co. Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
TiumBio Co. Ltd annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 226M | 1.13B | 1.11B | 1.05B | 56.8M | 9.12B | 4.90B | 6.79B | 12.3B | 14.9B |
| Gross Profit | - | - | - | 1.05B | 56.8M | 9.12B | 4.90B | 6.79B | 5.04B | 5.03B |
| Operating Income | -4.24B | -5.24B | -8.02B | -13.3B | -32.7B | -25.0B | -16.0B | -5.34B | -16.1B | -17.6B |
| EBITDA | - | - | - | - | - | -27.1B | -13.3B | -15.7B | -9.66B | -12.8B |
| Net Income | -8.79B | -13.8B | -7.09B | -12.1B | -31.6B | -29.9B | -17.9B | -20.6B | -17.4B | -19.4B |
| EPS | -379 | -593 | -302 | -510 | -1,323 | -1,243 | -727 | -773 | -590 | -660 |
| Balance Sheet | ||||||||||
| Total Assets | 10.1B | 29.3B | 93.5B | 85.4B | 117B | 96.3B | 120B | 107B | 98.6B | 91.0B |
| Total Liabilities | 17.2B | 575M | 958M | 2.84B | 29.2B | 35.2B | 49.2B | 54.8B | 60.8B | 58.5B |
| Shareholders' Equity | -7.09B | 28.7B | 92.5B | 82.5B | 87.6B | 61.0B | 70.1B | 52.5B | 40.8B | 36.1B |
| Cash & Short-term Investments | 6.27B | 24.4B | 88.9B | 68.6B | 40.6B | 18.1B | 34.4B | 47.7B | 10.8B | 3.69B |
| Total Debt | - | - | - | 931M | - | - | - | - | - | - |
| Cash Flow | ||||||||||
| Operating Cash Flow | -3.61B | -5.05B | -4.45B | -9.38B | -24.8B | -16.0B | -20.6B | -15.6B | -15.3B | -14.3B |
| Capital Expenditure | 3.46B | 237M | 503M | 867M | 11.8B | 11.2B | 18.4B | 1.04B | 382M | 1.27B |
| Free Cash Flow | - | - | - | -10.3B | -36.7B | -27.3B | -39.0B | -16.7B | -15.7B | -15.5B |
| Ratios | ||||||||||
| ROE | - | -47.8% | -7.7% | -14.7% | -36.1% | -48.9% | -25.6% | -39.3% | -42.5% | -53.8% |
| ROA | -86.9% | -46.9% | -7.6% | -14.2% | -27.1% | -31.0% | -15.0% | -19.2% | -17.6% | -21.3% |
| Net Profit Margin | -3,900.2% | -1,218.1% | -637.1% | -1,155.3% | -55,701.7% | -327.4% | -365.6% | -303.9% | -141.3% | -130.7% |
| Debt to Equity | - | - | - | 0.01x | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
TiumBio Co. Ltd dividends
TiumBio Co. Ltd has not paid dividends in the last 9 fiscal years.
Who owns TiumBio Co. Ltd
- Insiders 32.41%
- Institutions 8.99%
- Public & others 58.60%
- Shares outstanding 30.0M
- Free float 20.0M
TiumBio Co. Ltd company profile
- Company name
- TiumBio Co. Ltd
- Ticker
- 321550.KQ
- Exchange
- KOSDAQ
- Sector
- Healthcare
- Industry
- Oil, Gas & Consumable Fuels
- Employees
- 68
- Fiscal year end
- December
- Address
- 30, Changup-ro 40beongil, Seongnam-si, South Korea, 13493
- Phone
- 82 3 1600 1500
- Website
- tiumbio.com
About TiumBio Co. Ltd
TiumBio Co., Ltd., a drug discovery company, researches and develops therapeutics for patients with unaddressed rare diseases. The company's products pipeline includes chemical entity-based drugs and biopharmaceuticals comprising NCE401, NCE403, NCE406, and NBP604. It has a collaboration agreement with Oncodesign Société Anonyme for the research and development of fibrosis drug candidates. The company was founded in 2016 and is based in Seongnam-si, South Korea.
TiumBio Co. Ltd management
2- Mr. Huntaek KimChief Executive Officer · born 1966
- Ms. Hyunsil KohChief Financial Officer